PHAT reflux therapy targets $2B+ peak sales on strong adoption
PHAT’s gastroesophageal reflux therapy is cited as driving rapid revenue growth and profitability, with peak sales potential exceeding $2B across specialist and primary care channels, backed by pipeline expansion.